

Contributors

- P. J. Cowen**, *MRC Unit of Clinical Pharmacology, and University Department of Psychiatry, Littlemore Hospital, Oxford*
- A. G. Domantay**, *Central Nervous System Medical Planning, Bristol-Myers Squibb Company, Princeton, New Jersey, USA*
- C. A. Essau**, *Max Planck Institute for Psychiatry, Clinical Institute, Kraepelinstrasse 10, Munich, Germany*
- R. Kellner**, *Department of Psychiatry, University of New Mexico School of Medicine, 2400 Tucker NE, Albuquerque, USA*
- J.-C. Krieg**, *Max Planck Institute for Psychiatry, Clinical Institute, Kraepelinstrasse 10, Munich, Germany*
- M. Lader**, *Clinical Psychopharmacology, Institute of Psychiatry, De Crespigny Park, London*
- M. J. Napoliello**, *Central Nervous System Medical Planning, Bristol-Myers Squibb Company, and Clinical Assistant Professor of Psychiatry, Cornell University Medical College, Princeton, New Jersey, USA*
- G. D. Tollefson**, *Department of Psychiatry, St Paul-Ramsey Medical Center, 640 Jackson Street, St Paul, Minnesota, USA*
- P Tyrer**, *Department of Psychiatry, St Charles' Hospital, London*
- E. H. Uhlenhuth**, *Department of Psychiatry, University of New Mexico School of Medicine, 2400 Tucker NE, Albuquerque, USA*
- H.-U. Wittchen**, *Max Planck Institute for Psychiatry, Clinical Institute, Kraepelinstrasse 10, Munich, Germany*